GlassScriptPhysician profile
Puneet Dhillon
NPI 1710413539
$2,606.19
in general payments reported to CMS, 2019-2025
29 companies · $961 in 2025
The $961 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2021: $125 · 2022: $64.50 · 2023: $577 · 2024: $679 · 2025: $961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,892 · Honoraria: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,892.30 |
| Honoraria | $325.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $428.99 | 2024-2025 | Mycapssa |
| Novo Nordisk INC | $281.89 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Ascendis Pharma Endocrinology INC | $243.90 | 2023-2024 | |
| Medtronic, INC. | $155.59 | 2023 | Minimed 780g, Inpen Smart Insulin Delivery System, Ellipsys Vascular Access System |
| Lilly USA, LLC | $142.93 | 2022-2025 | Zepbound, Taltz, Mounjaro |
| Amgen INC. | $134.61 | 2024-2025 | Evenity, Tepezza, Prolia |
| Dexcom, INC. | $124.99 | 2023 | Dexcom G6 Transmitter |
| Pfizer INC. | $115.38 | 2019 | |
| Insulet Corporation | $113.61 | 2024-2025 | Omnipod |
| Neurocrine Biosciences, INC. | $111.42 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $111.03 | 2024 | |
| Corcept Therapeutics | $92.68 | 2023-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $84.01 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.63 | 2024 | Jardiance |
| Xeris Pharmaceuticals, INC. | $51.01 | 2024-2025 | Gvoke Hypopen, Recorlev |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $46.33 | 2024-2025 | Lupkynis |
| Sequel Med Tech, LLC | $41.08 | 2025 | Twiist |
| Astrazeneca Pharmaceuticals LP | $40.48 | 2023 | Farxiga |
| Soleno Therapeutics, INC. | $25.27 | 2025 | Vykat Xr |
| Ascensia Diabetes Care US INC. | $24.96 | 2023 | |
| Janssen Biotech, INC. | $24.72 | 2024 | Tremfya |
| Radius Health, INC. | $22.55 | 2025 | Tymlos |
| Sobi, INC | $20.68 | 2024 | |
| Sanofi-Aventis U.S. LLC | $20.48 | 2024 | |
| Alexion Pharmaceuticals, INC. | $18.97 | 2023 | Strensiq |
| Genentech USA, INC. | $17.53 | 2024 | Actemra |
| Mannkind Corporation | $16.88 | 2022 | |
| Amryt Pharma Holdings LTD | $13.72 | 2023 | Mycapssa |
| Tandem Diabetes Care, INC. | $12.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Puneet Dhillon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.